nonsmall-cell lung cancer
Conditions
Interventions
A:terellizumab combined with neoadjuvantchemotherapy
Sponsors
The Affiliated Hospital of Xuzhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 79 Years
Inclusion criteria
Inclusion criteria: 1.Older than 18 years old 2.Histologically confirmed stage II-IIIA NSCLC patients (Classification IASLC classification) 3.The evaluation by the thoracic surgeon confirmed compliance with the requirements for R0 resection for the purpose of radical treatment 4.The driver gene EGFR / ALK was negative 5.Patient compliance was good, and the screening period was able to provide complete tissue and blood samples 6.The patient had good liver and kidney, bone marrow function and other general indicators, and met the conditions for enrollment in general clinical trials 7.Subjects read and fully understood the patient instructions and signed the informed consent form
Exclusion criteria
Exclusion criteria: 1.Immunocompromised patients, or those currently undergoing systemic immunosuppressive therapy 2.Patients taking immunosuppressive drugs within two weeks prior to enrollment 3.Seriously infected patients with infectious disease that requires treatment with antimicrobial agents 4.Blood transfusion was performed within two weeks before surgery 5.The patient had a history of alcoholism or substance abuse 6.Pregnant or lactating female patient 7.Patients with incomplete samples during the screening period for various reasons 8.The investigator thinks it is not suitable for enrollment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| pCR; | — |
Countries
China
Contacts
Public ContactHao Zhang
Outcome results
None listed